Tempest Therapeutics Inc Stock Price, News & Analysis

Tempest Therapeutics, Inc. (TPST) recently announced the completion of enrollment in Phase 1 trials for TPST-1120, a PPARα antagonist, and presented promising preclinical data for TPST-1495 at the AACR Annual Meeting. The company reported a net loss of $8.5 million for Q1 2022, with cash reserves decreasing to $45.8 million, attributed to operational cash usage of $7.1 million. Amidst these financials, the company remains focused on upcoming clinical data presentations and has secured $15 million in PIPE financing to support ongoing development.

Tempest Therapeutics (Nasdaq: TPST) announced the acceptance of two abstracts for presentation at the 2022 ASCO Annual Meeting. An oral presentation will detail Phase 1 trial results for TPST-1120, a PPARα antagonist, while a poster presentation will cover the ongoing TPST-1495 trial. CEO Stephen Brady emphasized the significance of these presentations, marking Tempest's first clinical data release. The abstracts will be available on ASCO's website on May 26, 2022. Key presentation details include dates and titles relevant to ongoing clinical investigations.

Tempest Therapeutics, Inc. (Nasdaq: TPST) announced a $15 million PIPE financing, selling 3,149,912 shares at $2.36 each and pre-funded warrants at $2.359 to EcoR1 Capital and Versant Venture Capital. The financing aims to enhance the development of targeted cancer therapies. The transaction, expected to close by April 29, 2022, signifies trust from significant investors amidst current market conditions. The company plans to file a registration statement for the resale of shares involved in this placement.

Tempest Therapeutics (Nasdaq: TPST) presented promising preclinical data on April 8, 2022, regarding its innovative therapeutic programs at the AACR Annual Meeting. The data highlight the anti-tumor efficacy of TPST-1495, a dual antagonist targeting EP2 and EP4 receptors, showing superior tumor growth inhibition compared to single antagonists. Additionally, the TREX1 inhibitors demonstrated significant potential in activating the cGAS/STING pathway, crucial for immune response in tumors. These findings support ongoing clinical studies and underscore Tempest's commitment to developing first-in-class oncology treatments.

Tempest Therapeutics, Inc. (TPST) reported its financial results for 2021, highlighting significant achievements, including a successful merger and collaboration with Roche for TPST-1120. The company ended the year with $51.8 million in cash, a notable increase from $18.8 million in 2020. However, it recorded a net loss of $28.3 million, or $7.47 per share. R&D expenses rose to $17.2 million, indicating increased investment in drug development. Tempest anticipates presenting initial clinical data for TPST-1120 and TPST-1495 by early 2023, showcasing its robust cancer therapeutics pipeline.

Tempest Therapeutics (Nasdaq: TPST) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference on March 17, 2022, at 10:40 a.m. ET. The company is focused on developing first-in-class therapeutics that integrate targeted and immune-mediated mechanisms for various tumors. Its clinical-stage programs, TPST-1120 and TPST-1495, are currently in Phase 1 trials. The company collaborates with F. Hoffmann La Roche for a global Phase 1b/2 study of TPST-1120 in advanced liver cancer patients. More details can be accessed at Tempest's investor site.

Tempest Therapeutics (Nasdaq: TPST) announced two poster presentations at the 2022 AACR virtual annual meeting scheduled for April 8-13, 2022. The presentations feature new preclinical data on TPST-1495, a clinical-stage dual EP2/4 antagonist, and TREX1, a preclinical STING agonist. Key presentations include: TPST-1495 focusing on the dual blockade of PGE2 receptors and TREX1 aimed at activating STING in metastatic disease. Both programs are designed to enhance tumor treatment via targeted and immune-mediated approaches.

Tempest Therapeutics, a clinical-stage oncology company (Nasdaq: TPST), announced its participation in the 11th Annual SVB Leerink Healthcare Conference on February 16, 2022, at 2:20 PM ET. The company is known for developing innovative therapeutics that target tumors and harness immune responses. Presently, it is advancing two main programs, TPST-1120 and TPST-1495, through Phase 1 studies. TPST-1120 is also involved in a global Phase 1b/2 study in combination with atezolizumab and bevacizumab for treating advanced hepatocellular carcinoma. More details are available on their website.

Tempest Therapeutics (Nasdaq: TPST) announced the initiation of patient dosing with TPST-1495 in combination with pembrolizumab. This Phase 1a/1b study aims to optimize dosing schedules for patients with solid tumors. TPST-1495 targets the PGE2 pathway, which is linked to tumor growth and immune suppression. The study will evaluate safety, tolerability, and preliminary anti-tumor activity, focusing on prostaglandin-driven cancers. Tempest is exploring TPST-1495's potential to enhance treatment outcomes when combined with existing therapies.